Abstracts Archive - Page 1655 of 2425 - ACR Meeting Abstracts

Abstract Number: 2744 • 2015 ACR/ARHP Annual Meeting
What Is the Treatment Durability and Safety Profile of Rheumatoid Arthritis Patients Treated with Infliximab Plus Methotrexate and/or Leflunomide? an Analysis from a Real-World Registry
Rafat Faraawi¹, Raman Joshi², William G Bensen³, Denis Choquette⁴, Wojciech Olsynzynski⁵, Regan Arendse⁵, Maqbool Sheriff⁶, Proton Rahman⁷, Emmanouil Rampakakis⁸, Eliofotisti Psaradellis⁹, Francois Nantel¹⁰, Allen J Lehman¹¹, Susan Otawa¹¹, Cathy Tkaczyk¹¹ and Brendan Osborne¹¹, ¹McMaster University, Hamilton, ON, Canada, ²William Osler Health Centre-Brampton Civic Hospital, Brampton, ON, Canada, ³St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁴Rheumatology Department, Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ⁵University of Saskatchewan, Saskatoon, ON, Canada, ⁶Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁷Medicine, Memorial University, St John's, NF, Canada, ⁸JSS Medical Research, St-Laurent, QC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Clinical trials of anti-TNF therapies have shown that concurrent methotrexate (MTX) therapy enhances the efficacy of TNF inhibitors. A scarcity of data exists on…
Abstract Number: 2745 • 2015 ACR/ARHP Annual Meeting
Real World Evaluation of Patients with Rheumatoid Arthritis Initiating Tofacitinib Vs. Adalimumab and Etanercept
Benjamin Chastek¹, James Harnett², Jeffrey R. Curtis³, Robert Gerber⁴, David Gruben⁴, Rui Song⁵ and Andrew Koenig⁶, ¹Optum Insight, Eden Prairie, MN, ²Pfizer Inc, New York, NY, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Pfizer Inc, Groton, CT, ⁵Optum Insight, Reston, VA, ⁶Pfizer Inc, Collegeville, PA
Background/Purpose: In November 2012, the first oral Janus kinase (JAK) inhibitor tofacitinib was approved in the US for the treatment of RA with or without…
Abstract Number: 2746 • 2015 ACR/ARHP Annual Meeting
Comparison Study of Tests Available to Monitor Tocilizumab Therapy in Rheumatic Patients
Sergio Martín^1,2, Ainhoa Ruiz del Agua², Nerea Torres², Dora Pascual-Salcedo³, Chamaida Plasencia⁴, Teresa Jurado⁵, Alejandro Balsa⁶, Begoña Ruiz-Argüello², Antonio Martínez², Rosaura Navarro⁷ and Daniel Nagore², ¹Department of Physiology, Medicine and Dentistry School, University of the Basque Country UPV/EHU (Convocatoria ZabaldUZ, UPV/EHU; Departamento de Educación, Universidades e Investigación del Gobierno Vasco, Ref. IT687-13), Leioa, Spain, ²R&D, Progenika-Grifols, Derio, Spain, ³Immunology Unit, La Paz University Hospital-Immunology, Madrid, Spain, ⁴Rheumatology Unit, La Paz University Hospital-Rheumatology, Madrid, Spain, ⁵Immunology, La Paz University Hospital-Idipaz, Madrid, Spain, ⁶Rheumatology, La Paz University Hospital-Rheumatology Department, Madrid, Spain, ⁷Department of Physiology, Medicine and Dentistry School, University of the Basque Country UPV/EHU, Leioa, Spain
Background/Purpose: The options for treatment of rheumatic diseases is constantly growing. Tocilizumab (TCZ) is an anti-interleukin 6 receptor monoclonal antibody indicated for the treatment of severe…
Abstract Number: 2747 • 2015 ACR/ARHP Annual Meeting
Study Completion and Etanercept Retention in Patients with Rheumatoid Arthritis Treated with Etanercept Monotherapy Versus Etanercept and Methotrexate Combination Therapy
Janet E. Pope¹, Edward C. Keystone², J Carter Thorne³, Melanie Poulin-Costello⁴, Krystene Phan-Chronis⁴ and Boulos Haraoui⁵, ¹University of Western Ontario, London, ON, Canada, ²Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Southlake Regional Health Centre, Newmarket, ON, Canada, ⁴Amgen Canada Inc., Mississauga, ON, Canada, ⁵University of Montreal Hospital Centre, Montreal, QC, Canada
Background/Purpose: The CAnadian Methotrexate and Etanercept Outcome (CAMEO) study, an open-label trial in patients with active rheumatoid arthritis (RA), revealed that patients achieving low disease…
Abstract Number: 2748 • 2015 ACR/ARHP Annual Meeting
Evaluation of Patient-Reported Outcomes By Baseline Disease Duration: 6-Month Data from Two Clinical Trials of Patients with Early Rheumatoid Arthritis Treated with Abatacept
Daniel E. Furst¹, VP Bykerk², Gerd Burmester³, BG Combe⁴, T. W. J. Huizinga⁵, E Alemao⁶, A Johnsen⁶ and Paul Emery⁷, ¹Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Weill Cornell Medical College, New York, NY, ³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Montpellier University, Montpellier, France, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Bristol-Myers Squibb, Princeton, NJ, ⁷University of Leeds, Leeds, United Kingdom
Background/Purpose: Patients with RA and longer disease duration generally do not respond as well to treatment with DMARDs as patients with shorter duration of disease.…
Abstract Number: 2749 • 2015 ACR/ARHP Annual Meeting
A Phase 1 Study of FPA008, an Anti-Colony Stimulating Factor 1 Receptor (anti-CSF1R) Antibody in Patients (pts) with Rheumatoid Arthritis (RA): Preliminary Results
Lei Zhou¹, Robert Sikorski¹, Seema Rogers¹, Stefan Costin², Mariusz Korkosz³, Maria Jaraczewska-Baumann⁴, Péterfai Éva⁵, Bernadette Rojkovich⁶, Janos Bartalos⁷, Emma Masteller¹, Hong Xiang¹, Brian Wong¹ and Julie Hambleton¹, ¹Five Prime Therapeutics, Inc., South San Francisco, CA, ²PRA Heath Sciences, Berlin, Germany, ³Malopolskie Centrum Medyczne, The University Hospital in Krakow, Krakow, Poland, ⁴MedPolonia Sp. z o.o, Poznan, Poland, ⁵Drug Research Center, Balatonfüred, Hungary, ⁶Hospitaller Brothers of St. John of God, Budapest, Hungary, ⁷PRA Hungary Ltd, Budapest, Hungary
Background/Purpose: FPA008 is a humanized IgG4 anti-CSF1R antibody that blocks the binding of CSF1 and IL34 ligands to CSF1R, resulting in inhibition of the activation…
Abstract Number: 2750 • 2015 ACR/ARHP Annual Meeting
Tocilizumab Is Effective As 1st, 2nd and 3rd-Line Biologic DMARD in Patients with Rheumatoid Arthritis
Adrian Richter¹, Anja Strangfeld², Joern Kekow³, Arnold Bussmann⁴, Andreas Krause⁵, Carsten Stille⁶, Joachim Listing⁷ and Angela Zink⁸, ¹German Rheumatism Research Center, Berlin, Germany, ²Epidemiology, German Rheumatism Research Center, Berlin, Germany, ³University of Magdeburg, Magdeburg, Germany, ⁴Rheumatologist, Geilenkirchen, Germany, ⁵Rheumatologist, Berlin, Germany, ⁶Rheumatologist, Hannover, Germany, ⁷Epidemiology, DRFZ, Berlin, Germany, ⁸Epidemiologie, Deutsches Rheuma-Forschungszentrum, Berlin, Germany
Background/Purpose: In Germany, treatment with Tocilizumab (TCZ) is primarily used in rheumatoid arthritis patients with previous failures of biologic DMARDs. Effectiveness and adherence of TCZ…
Abstract Number: 2751 • 2015 ACR/ARHP Annual Meeting
Assessment of the Effect of CYP3A Inhibition, CYP Induction, OATP1B Inhibition and Administration of High-Fat Meal on the Pharmacokinetics of the Potent and Selective JAK1 Inhibitor ABT-494
Mohamed-Eslam Mohamed¹, Steven Jungerwirth², Armen Asatryan¹, Ping Jiang² and Ahmed Othman¹, ¹AbbVie, North Chicago, IL, ²AbbVie Inc., North Chicago, IL
Background/Purpose: ABT‑494 is an oral selective JAK1 inhibitor that is being developed for treatment of rheumatoid arthritis and Crohn’s disease. ABT-494 is metabolized by cytochrome…
Abstract Number: 2752 • 2015 ACR/ARHP Annual Meeting
Profile of Joint Involvement over Time in Rheumatoid Arthritis and Psoriatic Arthritis Patients Treated with Anti-TNF in a Real-World Setting
Algis Jovaisas¹, Michael Starr², Denis Choquette³, Michel Zummer⁴, Regan Arendse⁵, Dalton Sholter⁶, Rafat Faraawi⁷, Jude Rodrigues⁸, Emmanouil Rampakakis⁹, John S. Sampalis⁹, Francois Nantel¹⁰, Allen J Lehman¹¹, Susan Otawa¹¹, May Shawi¹⁰ and Karina Maslova¹⁰, ¹Capital North Therapeutics & Research, Ottawa, ON, Canada, ²Rheumatology, McGill University, Montreal, QC, Canada, ³Rheumatology, Institut de recherche en rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ⁴Université de Montréal, Quebec, QC, Canada, ⁵University of Saskatchewan, Saskatoon, SK, Canada, ⁶Rheumatology Associates, Edmonton, AB, Canada, ⁷McMaster University, Hamilton, ON, Canada, ⁸Jude Rodrigues Medicine Professional Corporation, Windsor, ON, Canada, ⁹JSS Medical Research, St-Laurent, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: : Unlike rheumatoid arthritis (RA), the pattern of joint involvement in psoriatic arthritis (PsA) is usually asymmetric. Furthermore, PsA may demonstrate oligoarthritis or polyarthritis,…
Abstract Number: 2753 • 2015 ACR/ARHP Annual Meeting
Effectiveness and Safety of Tocilizumab in Biologics-Naive RA Patients – Postmarketing Surveillance for Investigating Success in Achieving Clinical and Functional Remission and Sustaining Efficacy with Tocilizumab in Biologics-Naive RA Patients (FIRST Bio) Study
Naoki Ishiguro¹, Tatsuya Atsumi², Masayoshi Harigai³, Tsuneyo Mimori⁴, Norihiro Nishimoto⁵, Takayuki Sumida⁶, Tsutomu Takeuchi⁷, Yoshiya Tanaka⁸, Nobuhiro Takagi⁹, Ayako Nakasone¹⁰ and Hisashi Yamanaka¹¹, ¹Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan, ²Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ³Department of Phamacovigilance, Tokyo Medical and Dental University, Tokyo, Japan, ⁴Dept of Rheum & Clinical Immun, Kyoto Univ Grad Schl of Med, Kyoto, Japan, ⁵Osaka Rheumatology Clinic, Osaka, Japan, ⁶Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ⁷Keio University School of Medicine, Tokyo, Japan, ⁸The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁹Medical Science, Chugai Pharmaceutical, Tokyo, Japan, ¹⁰Chugai Pharmaceutical Co. Ltd, Tokyo, Japan, ¹¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: The all-patient postmarketing surveillance (PMS) of tocilizumab (TCZ; PMS7901), which followed 7901 rheumatoid arthritis (RA) patients for 28 weeks (wks), showed that patients with…
Abstract Number: 2754 • 2015 ACR/ARHP Annual Meeting
Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of BI 655064, an Antagonistic Anti-CD40 Antibody Following Single-Dose Administration in Chinese and Japanese Healthy Volunteers
Jiyoon Kim¹, Yasuhiro Tsuda², Kazuhiko Yamamoto³, Ralf Thiedmann⁴, Corinna Schoelch⁴, Stephen Norris⁵, Steven Padula⁶, Juergen Steffgen⁴ and In-Jin Jang⁷, ¹Boehringer Ingelheim Korea Ltd., Seoul, South Korea, ²Clinical PK/PD department, Nippon Boehringer-Ingelheim.Co.,Ltd., Kobe, Japan, ³Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ⁴Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, ⁵Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, ⁶Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany, ⁷Seoul National University Hospital, Seoul, South Korea
Background/Purpose: The CD40-CD40L pathway may play a major role in autoimmune disorders like rheumatoid arthritis or SLE. Blocking this pathway may be a promising new…
Abstract Number: 2755 • 2015 ACR/ARHP Annual Meeting
Evaluating Pharmacokinetic Predictors of Tofacitinib Clinical Response in Rheumatoid Arthritis
Manisha Lamba¹, Daniel E. Furst², Ara Dikranian³, Martin Dowty¹, Matthew M Hutmacher⁴, Daniela Conrado¹, Thomas Stock⁵, Chudy Nduaka⁵ and Sriram Krishnaswami¹, ¹Pfizer Inc, Groton, CT, ²Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³San Diego Arthritis Medical Clinic, San Diego, CA, ⁴Ann Arbor Pharmacometrics Group, Ann Arbor, MI, ⁵Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. A modified-release (MR) formulation to provide a once-daily (QD) dosing alternative to…
Abstract Number: 2756 • 2015 ACR/ARHP Annual Meeting
Impact of Tocilizumab Monotherapy on Patient-Reported Quality of Life Outcomes in the US Corrona Registry
Leslie Harrold^1,2, Ani John³, George W. Reed^2,4, Chitra Karki², YouFu Li⁴, Joel M. Kremer⁵, Tmirah Haselkorn⁶ and Jeffrey D. Greenberg^2,7, ¹Department of Orthopedics and Medicine, University of Massachusetts Medical School, Worcester, MA, ²Corrona, LLC, Southborough, MA, ³Genentech, Inc., South San Francisco, CA, ⁴University of Massachusetts Medical School, Worcester, MA, ⁵Albany Medical College, Albany, NY, ⁶Genentech, Inc, South San Francisco, CA, ⁷NYU School of Medicine, New York, NY
Background/Purpose: The objective of this real-world analysis was to examine the impact of the interleukin-6 receptor α inhibitor tocilizumab (TCZ) on patient-reported outcomes (PROs) in…
Abstract Number: 2757 • 2015 ACR/ARHP Annual Meeting
Secondary Efficacy Endpoints: Results from a Phase 3 Study Comparing ABP 501 with Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis
Alan K. Matsumoto¹, Karel Pavelka², Warren Rizzo³, Ramesh Gupta⁴, William Shergy⁵, Pawel Heycaj⁶, Nan Zhang⁷ and Primal P. Kaur⁸, ¹Rheumatology, Arthritis & Rheumatism Assoc, Wheaton, MD, ²Charles University, Prague, Czech Republic, ³Advanced Arthritis Care & Research, Scottsdale, AZ, ⁴Private Practice, Rheumatology, Memphis, TN, ⁵RANA Clinical Research Center, Huntsville, AL, ⁶Rheumatology and Clinical Immunology, Poznañ University of Medical Sciences, Poznan, Poland, ⁷Biosimilars, Amgen, Inc., Thousand Oaks, CA, ⁸Amgen, Inc., Thousand Oaks, CA
Background/Purpose: ABP 501 is being developed as a biosimilar candidate to adalimumab (Humira®), a fully human recombinant monoclonal antibody. Evidence from analytical and pharmacokinetic comparisons…
Abstract Number: 2758 • 2015 ACR/ARHP Annual Meeting
Clinical Utility and Factors Associated with Certolizumab Pegol Drug Levels and Anti-Drug Antibodies in the Long-Term Treatment of Rheumatoid Arthritis
Meghna Jani¹, Hector Chinoy^1,2, John Isaacs³, Ann W. Morgan⁴, Anthony Wilson⁵, Kimme L. Hyrich⁶, Darren Plant^1,2 and Anne Barton^1,7, ¹Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ²NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, ³National Institute for Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle, United Kingdom, ⁴NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds & Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Infection & Immunity, University of Sheffield, Sheffield, United Kingdom, ⁶Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁷NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester Foundation Trust and University of Manchester, Manchester Academy of Health Sciences, Manchester, United Kingdom
Background/Purpose: Up to 40% of RA patients on anti-TNF agents fail to respond either due to primary or secondary inefficacy. One explanation is immunogenicity leading…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].